Revenue fell 34.6% to ¥1.73 billion, but net profit surged 67.2% to ¥397 million, driven by core blood product growth and a low base effect. The company expanded its plasma station network and completed a major acquisition, while maintaining a 40.65% dividend payout ratio.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.